Avadel Pharmaceuticals Reports Strong Financial Results

Avadel Pharmaceuticals, a biopharmaceutical company, has reported its fourth-quarter and full-year 2023 financial results in a recent corporate update. The company generated $19.5 million in net revenue from sales of Lumryz™ in the fourth quarter and $28.0 million for the full year 2023.

By the end of January 2024, over 2,200 patients were enrolled in Ryzu™, and more than 1,200 patients had initiated therapy with Lumryz. Avadel has secured payer coverage for over 80% of commercially covered lives for Lumryz, including listings with United Healthcare and Anthem.

The U.S. Food and Drug Administration (FDA) has set a target action date of September 7, 2024, for the supplemental new drug application (SNDA) for Lumryz in pediatric narcolepsy.

In terms of financial performance, Avadel recognized $19.5 million and $28.0 million in net product revenue for the fourth quarter and full year 2023, respectively. Research and development (R&D) expenses decreased to $2.4 million and $13.3 million for the quarter and year ended December 31, 2023, from $6.2 million and $20.7 million for the same periods in 2022.

Selling, general, and administrative (SG&A) expenses increased to $41.3 million and $151.7 million for the quarter and year ended December 31, 2023, from $17.0 million and $74.5 million for the same periods in 2022. The net losses for the quarter and year ended December 31, 2023, were $28.8 million and $160.3 million, respectively.

As of December 31, 2023, Avadel had cash, cash equivalents, and marketable securities totaling $105.1 million.

The company plans to host a conference call at 7:30 a.m. ET to discuss these results and provide further insights.

Lumryz, an extended-release sodium oxybate medication, was approved by the FDA as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The FDA approval was supported by results from the REST-ON trial, demonstrating statistically significant and clinically meaningful improvements in various endpoints.

The market has reacted to these announcements by moving the company's shares 11.2% to a price of $15.25. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.